A Case Report of a Patient with Metastatic Uveal Melanoma who Experienced a Complete Response to Treatment with the NIVO3+IPI1 Regimen
Uveal melanoma is a rare malignancy and in the advanced setting there is no effective treatment. Therefore, combined checkpoint blockade with nivolumab 1 mg/kg and ipilimumab 3 mg/kg (NIVO1+IPI3) is frequently used despite low response rates and high immune-related toxicity. There are hardly any reports on the less toxic combination of nivolumab 3 mg/kg and ipilimumab 1 mg/kg schedule (NIVO3+IPI1) in these patients. Case presentation: We used the NIVO3+IPI1 schedule to treat a 56-year-old male suffering from metastatic uveal melanoma. The patient experienced a clear and long-lasting benefit from the treatment. An improvement of his general condition was observed almost immediately after treatment start. A complete metabolic response which is still ongoing was achieved over a year ago and a complete response according to RECIST 1.1 criteria was evident at the most recent CT scan. Conclusions: To our knowledge, this is the first described case of complete response to NIVO3+IPI1combined immunotherapy in a patient with metastatic uveal melanoma.